Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms

Cholesterol, Cytokines and Diseases

(2017) A. Saggini et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-  in a murine model of polycythemia vera

(2013) A. Mullally et al.   BLOOD

JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN 

(2013) S. Hasan et al.   BLOOD

Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinibversusbest available therapy

(2013) Claire N. Harrison et al.   BRITISH JOURNAL OF HAEMATOLOGY

Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study

(2013) Sarah Farmer et al.   BRITISH JOURNAL OF HAEMATOLOGY

The role of cytokines in the initiation and progression of myelofibrosis

(2013) Hans C. Hasselbalch   CYTOKINE & GROWTH FACTOR REVIEWS

Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial

(2013) Ruben A. Mesa et al.   JOURNAL OF CLINICAL ONCOLOGY

A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression

(2013) C Marty et al.   LEUKEMIA

Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis

(2013) Vibe Skov et al.   LEUKEMIA & LYMPHOMA

Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study

(2013) Ruben A. Mesa et al.   LEUKEMIA RESEARCH

Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha

(2013) Thomas Stauffer Larsen et al.   LEUKEMIA RESEARCH

Myelodysplastic syndromes and autoimmune diseases—Case series and review of literature

(2013) Omar Al Ustwani et al.   LEUKEMIA RESEARCH

JAK2 Mutation-Related Disease and Thrombosis

(2013) Paola Guglielmelli et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis

(2013) Richard T Silver et al.   Expert Review of Hematology

Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort

(2012) P. J. Campbell et al.   BLOOD

Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors

(2012) V. Gupta et al.   BLOOD

Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?

(2012) H. C. Hasselbalch   BLOOD

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

(2012) S. Verstovsek et al.   BLOOD

JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth

(2012) Lori N. Griner et al.   BRITISH JOURNAL OF HAEMATOLOGY

Interferon-Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives

(2012) Hans Carl Hasselbalch et al.   CURRENT DRUG TARGETS

Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?

(2012) Hans Carl Hasselbalch   LEUKEMIA RESEARCH

Challenges Facing JAK Inhibitor Therapy for Myeloproliferative Neoplasms

(2012) Ayalew Tefferi   NEW ENGLAND JOURNAL OF MEDICINE

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Events and Intensity of Treatment in Polycythemia Vera

(2012) Roberto Marchioli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis

(2012) Giovanni Barosi et al.   PLoS One

TNF  facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms

(2011) A. G. Fleischman et al.   BLOOD

Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study

(2011) H. Frederiksen et al.   BLOOD

Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN- 

(2011) C. H. Riley et al.   BLOOD

Therapeutic approaches in myelofibrosis

(2011) Giovanni Barosi et al.   EXPERT OPINION ON PHARMACOTHERAPY

Immunomodulatory therapy for sepsis: an update

(2011) Eirini Christaki et al.   Expert Review of Anti-Infective Therapy

Hydroxycarbamide: a user’s guide for chronic myeloproliferative disorders

(2011) Jerry L Spivak et al.   Expert Review of Anticancer Therapy

Interferon Alfa in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms

(2011) Hans Carl Hasselbalch et al.   JOURNAL OF CLINICAL ONCOLOGY

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980

(2011) Jean-Jacques Kiladjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes

(2011) Sigurdur Y. Kristinsson et al.   JOURNAL OF CLINICAL ONCOLOGY

Hydroxyurea induces de novo copy number variants in human cells

(2011) M. F. Arlt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus

(2011) J Michelle Kahlenberg et al.   ARTHRITIS RESEARCH & THERAPY

A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms

(2011) Hans Carl Hasselbalch   Expert Review of Hematology

Therapeutic Potential of Janus-activated Kinase-2 Inhibitors for the Management of Myelofibrosis

(2010) S. Verstovsek   CLINICAL CANCER RESEARCH

The Anti-Ischemic and Anti-Anginal Properties of Statins

(2010) Joel A. Lardizabal et al.   Current Atherosclerosis Reports

Risk factors and early detection of atherosclerosis in rheumatoid arthritis

(2010) Lodewijk De Groot et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Autoimmunity and the risk of myeloproliferative neoplasms

(2010) S. Y. Kristinsson et al.   HAEMATOLOGICA

Cancer and Inflammation: Promise for Biologic Therapy

(2010) Sandra Demaria et al.   JOURNAL OF IMMUNOTHERAPY

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

(2010) A Tefferi   LEUKEMIA

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications

(2010) F Passamonti et al.   LEUKEMIA

LNKMutations inJAK2Mutation–Negative Erythrocytosis

(2010) Terra L. Lasho et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK2 Mutation and Thrombosis in the Myeloproliferative Neoplasms

(2010) Alessandro M. Vannucchi   Current Hematologic Malignancy Reports

How I treat symptomatic splenomegaly in patients with myelofibrosis

(2009) R. A. Mesa   BLOOD

Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation

(2009) M. Rotta et al.   BLOOD

Risks of myeloid malignancies in patients with autoimmune conditions

(2009) L A Anderson et al.   BRITISH JOURNAL OF CANCER

Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms

(2009) A. M. Vannucchi et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission

(2009) Thomas Stauffer Larsen et al.   Hematology

Autoimmunity and hematologic malignancies: associations and mechanisms

(2009) Damali N. Martin et al.   LEUKEMIA & LYMPHOMA

IFNα activates dormant haematopoietic stem cells in vivo

(2009) Marieke A. G. Essers et al.   NATURE

Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera

(2008) T. S. Larsen et al.   ANNALS OF HEMATOLOGY

Primary Myelofibrosis: Update on Definition, Pathogenesis, and Treatment

(2008) Omar I. Abdel-Wahab et al.   Annual Review of Medicine

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

(2008) J.-J. Kiladjian et al.   BLOOD

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

(2008) A M Vannucchi et al.   LEUKEMIA

Myelofibrosis with myeloid metaplasia: The advanced phase of an untreated disseminated hematological cancer

(2008) Hans Carl Hasselbalch   LEUKEMIA RESEARCH